Mitch Tompkins’ Post

Enterprise AI is at a crossroads between the well-lit path to modest, incremental benefits and the uncertain, more difficult path to breakthroughs that change the trajectory of your business, explained Domino Data Lab COO Thomas Robinson at RevX London. His keynote covered the methods Domino customers build and test AI-based investment strategies 4x faster and bringing life-saving medicine to market faster while complying with stringent regulatory requirements. You’ve experimented with Gen AI and deployed initial use cases. Now, which path will you take? #AI #Innovation #AIValue #DataScience #RevX24

Enterprise AI is at a crossroads between the well-lit path to modest, incremental benefits and the uncertain, more difficult path to breakthroughs that change the trajectory of your business, explained Domino Data Lab COO Thomas Robinson at RevX London. His keynote covered the methods Domino customers build and test AI-based investment strategies 4x faster and bringing life-saving medicine to market faster while complying with stringent regulatory requirements. You’ve experimented with Gen AI and deployed initial use cases. Now, which path will you take? #AI #Innovation #AIValue #DataScience #RevX24

Enterprise AI is at a crossroads between the well-lit path to modest, incremental benefits and the uncertain, more difficult path to breakthroughs that change the trajectory of your business, explained Domino Data Lab COO Thomas Robinson at RevX London. His keynote covered the methods Domino customers build and test AI-based investment strategies 4x faster and bringing life-saving medicine to market faster while complying with stringent regulatory requirements. You’ve experimented with Gen AI and deployed initial use cases. Now, which path will you take? #AI #Innovation #AIValue #DataScience #RevX24

Enterprise AI is at a crossroads between the well-lit path to modest, incremental benefits and the uncertain, more difficult path to breakthroughs that change the trajectory of your business, explained Domino Data Lab COO Thomas Robinson at RevX London. His keynote covered the methods Domino customers build and test AI-based investment strategies 4x faster and bringing life-saving medicine to market faster while complying with stringent regulatory requirements. You’ve experimented with Gen AI and deployed initial use cases. Now, which path will you take? #AI #Innovation #AIValue #DataScience #RevX24

Enterprise AI is at a crossroads between the well-lit path to modest, incremental benefits and the uncertain, more difficult path to breakthroughs that change the trajectory of your business, explained Domino Data Lab COO Thomas Robinson at RevX London. His keynote covered the methods Domino customers build and test AI-based investment strategies 4x faster and bringing life-saving medicine to market faster while complying with stringent regulatory requirements. You’ve experimented with Gen AI and deployed initial use cases. Now, which path will you take? #AI #Innovation #AIValue #DataScience #RevX24

Enterprise AI is at a crossroads between the well-lit path to modest, incremental benefits and the uncertain, more difficult path to breakthroughs that change the trajectory of your business, explained Domino Data Lab COO Thomas Robinson at RevX London. His keynote covered the methods Domino customers build and test AI-based investment strategies 4x faster and bringing life-saving medicine to market sooner while complying with stringent regulatory requirements. You’ve experimented with Gen AI and deployed initial use cases. Now, which path will you take? #AI #Innovation #AIValue #DataScience #RevX24

Enterprise AI is at a crossroads between the well-lit path to modest, incremental benefits and the uncertain, more difficult path to breakthroughs that change the trajectory of your business, explained Domino Data Lab COO Thomas Robinson at RevX London. His keynote covered the methods Domino customers build and test AI-based investment strategies 4x faster and bringing life-saving medicine to market faster while complying with stringent regulatory requirements. You’ve experimented with Gen AI and deployed initial use cases. Now, which path will you take? #AI #Innovation #AIValue #DataScience #RevX24

As a proud partner of ValGenesis, Performance Validation is excited to share insights into the revolutionary ValGenesis VLMS 5.0. This next-generation platform is designed to transform how life sciences companies manage validation, combining AI-driven innovation with a user-friendly interface that prioritizes both power and usability. In our latest blog, we explore how VLMS 5.0 sets new standards in efficiency, compliance, and collaboration. From proactive risk management to streamlined workflows, discover why VLMS 5.0 is a game-changer for validation lifecycle management. 👉 Read more about how VLMS 5.0 can elevate your validation processes: https://bit.ly/3Z9aeTQ This article was originally published on ValGenesis and is shared here with permission. #DigitalTransformation #LifeSciences #Validation #AI #Compliance #ValGenesis #PerformanceValidation

How would you feel when the global leader in software M&A Corum Group Ltd. Nihat Arkan shows the slide with Top Disruptive Technology Trends that exactly matches existing and planned capabilities of your product? I feel super excited! LLM-based AI tools are everywhere, but industry solutions that use customer big data for Actionable Analytics are very limited. #HiPerWare platform offers time series AI analytics, based on collected Big Data and library of anomalies. I can compare it to a medical diagnostic device with built-in AI medical encyclopedia. 📩 Let me know if you're interested to get real business benefits from AI tools and your own big data for energy efficiency and predictive maintenance.

My quick thoughts about the pent-up innovation inside the enterprise that is set to explode with those who make GenAI a priority. This video was in support of a great article from Brett A. Hurt around the same topic. You can read that here: https://lnkd.in/gwBBbX4M https://lnkd.in/gvDyRKZN